A Study of LY3561774 in Participants With Mixed Dyslipidemia

Exclusion Criteria

• •Have in the 6 months prior to screening, uncontrolled Type 1 or Type 2 diabetes, defined as an episode of ketoacidosis or hyperosmolar state requiring hospitalization, or have an hemoglobin A1c (HbA1c) ≥8% at screening.
• •Have a history of nephrotic syndrome.
• •Have a history of acute or chronic pancreatitis.
• •Have had within the past 3 months prior to screening
• •* Myocardial infarction
• •* Unstable angina
• •* Coronary artery bypass graft
• •* Percutaneous coronary intervention - diagnostic angiograms are permitted
• •* Peripheral artery disease
• •* Transient ischemic attack, or
• •* Cerebrovascular accident
• •Have New York Heart Association Class III or IV heart failure or last known left ventricular ejection fraction \<30%.
• •Have undergone LDL apheresis within 12 months prior to screening.
• •Have clinically relevant anemia, as defined by the investigator.
• •Have, within 1 year prior to screening or plan on having during the study, surgical treatment for obesity.
• •Have within 3 years prior to screening a history of chronic alcohol abuse, IV drug abuse, or other illicit drug abuse.
• •Have uncontrolled hypertension.
• •Have used or are taking products for the purpose of lowering lipid levels (except for statins, PCSK9 inhibitors, bempedoic acid, and ezetimibe). This includes lipid-regulating medication, over-the-counter products, or herbal therapies.